Phase 4 N=80 A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy
Muscle Weakness | Patient · Pain
Primary: Numeric Pain Score — 7; 6 units on the numeric rating scale (0-10)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=199 Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
HIV Infections
Primary: Number of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities That Occur From the Initial Injection to Week 41…
Phase 2 N=89 Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
Stable Angina
Primary: Change From Baseline in Total Exercise Time — 8.1; -2.9 seconds
Phase 2 N=24 Vilazodone for Corticosteroid-Induced Memory Impairment
Memory Impairment
Primary: Change From Baseline RAVLT (Rey Auditory Verbal Learning Test) Total T-Score at Day 19 — -3; 0 T-score
N/A N=352 Clinical Trial of Protein and Blood Pressure
Hypertension · Hypercholesterolemia
Primary: Change From Baseline in Average Systolic Blood Pressure at 8 Weeks — -1.5; -1.8; 0.5 mmHg
Phase 2 N=64 Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
Patients, Resistant Hypertension
Primary: Number of Participants With Reported Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths — 12; 3; 14; 0 Participants
Phase 3 N=208 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
N/A N=537 A Trial of a Comprehensive Breast Cancer Treatment Patient Decision Tool
Breast Cancer
Primary: Number of Patients With Accurate Knowledge About Risks and Benefits of Treatment Options for Locoregional Breast Cancer. — 148; 105 Participants
N/A N=7 E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia
Tobacco Smoking
Primary: Change in Smoking as Assessed by Breath Carbon Monoxide Levels — -18; -4.3 parts per million (ppm)
Phase 3 N=140 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
Lymphoma, Non Hodgkin
Primary: Percentage of Participants With Administration-Associated Reactions (AARs) — 34.5; 52.3; 48.6; 0 percentage of participants
Phase 3 N=53 Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics
Helicobacter Pylori Infection
Primary: Number of Participants With Reported Adverse Events — 1 Participants
Phase 2 N=123 Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control
Ovulation Suppression
Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation
Phase 2 N=30 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Adult Ependymoblastoma · Adult Giant Cell Glioblastoma · Adult Glioblastoma
Primary: Dose-limiting Toxicity — 0; 0; 0 Participants
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=60 Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
Marijuana Use · Pregnancy
Primary: Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery — 6; 7; 6; 3 Participants